-

Shareholder Alert: Robbins LLP Announces that Odonate Therapeutics, Inc. (ODT) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) has filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 7, 2017 and August 21, 2020. Based in San Diego, California, Odonate is a pharmaceutical company that develops therapeutics for the treatment of cancer. The Company is developing tesetaxel, an oral chemotherapy.

If you suffered a loss due to Odonate Therapeutics, Inc.'s misconduct, click here.

Odonate Therapeutics, Inc. (ODT) Accused of Misrepresenting Potential of New Cancer Drug

According to the complaint, during the relevant period, Odonate Therapeutics, Inc. touted the extent of its clinical trials of tesetaxel and the efficacy of the drug. Unbeknownst to shareholders, Odonate Therapeutics failed to disclose the serious safety and tolerance issues surrounding tesetaxel, which has compromised the drug's potential commercial viability as a cancer treatment. Before market hours on August 24, 2020, Odonate released its CONTESSA trial results, shocking investors with the announcement that tesetaxel substantially increased neutropenia (low white blood cell counts), neuropathy, and other adverse events. The trial results demonstrated a discontinuation rate of just 11.9% in the control group versus 23.1% in the tesetaxel treatment group. On this news, Odonate stock price fell 43.35% to close at $18.33 per share on August 24, 2020.

If you purchased Odonate Therapeutics, Inc. (ODT) securities between December 7, 2017 and August 21, 2020, you have until November 16, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against American Electric settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:ODT
Release Versions
English
$Cashtags
$ODT
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom